Author:
Friedlander Michael,Trimble Edward,Tinker Anna,Alberts David,Avall-Lundqvist Elisabeth,Brady Mark,Harter Philipp,Pignata Sandro,Pujade- Lauraine Eric,Sehouli Jalid,Vergote Ignace,Beale Philip,Bekkers Rudd,Calvert Paula,Copeland Lawrence,Glasspool Ros,Gonzalez-Martin Antonio,Katsaros Dionysis,Kim Jae Won,Miller Brigitte,Provencher Diane,Rubinstein Lawrence,Atri Mostafa,Zeimet Alain,Bacon Monica,Kitchener Henry,Stuart Gavin C.E.
Abstract
The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?
Subject
Obstetrics and Gynecology,Oncology